Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune modulatory therapies.
Deciduous Therapeutics has raised $10.0M in total funding. The most recent round was Seed. The last funding was announced in December 2022.
Deciduous Therapeutics's investors include 8VC, Global Brain Corporation, CRV, Presight Capital, The Longevity Fund.
Deciduous Therapeutics is headquartered in San Francisco, United States.
Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune modulatory therapies.
Deciduous Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Deciduous Therapeutics — Funding & Investors." VCBacked, December 31, 2022, https://www.vcbacked.co/company/deciduous-therapeutics. Accessed October 16, 2026.
VCBacked. (2022). Deciduous Therapeutics — Funding & Investors. Retrieved October 16, 2026, from https://www.vcbacked.co/company/deciduous-therapeutics
{{cite web |title=Deciduous Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/deciduous-therapeutics |website=VCBacked |access-date=October 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated